Neil Levin, MD
Nuclear Cardiology · Philadelphia, PANPI 1053343368
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by Atricure, Inc. at 49.3% of the total.
Across 5 payments — averaging $35.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Atricure, Inc.$87
- Novo Nordisk$59
- Boston Scientific$30
What the payments were for
- Food & beverage$177100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Atricure, Inc. | 1 | $87 |
| Novo Nordisk | 3 | $59 |
| Boston Scientific | 1 | $30 |
How this compares
Too few nuclear cardiology providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 164 | $188,295 |
| XareltoRivaroxaban | 73 | $92,077 |
| Repatha SureclickEvolocumab | 75 | $61,974 |
| EntrestoSacubitril/Valsartan | 40 | $44,077 |
| Praluent PenAlirocumab | 44 | $27,729 |
| Metoprolol Succinate | 300 | $4,486 |
| Atorvastatin Calcium | 466 | $4,387 |
| Ezetimibe | 139 | $3,312 |
| Valsartan | 52 | $2,187 |
| Losartan Potassium | 159 | $1,701 |
| Amlodipine Besylate | 242 | $1,701 |
| Rosuvastatin Calcium | 153 | $1,467 |
| ClopidogrelClopidogrel Bisulfate | 73 | $1,397 |
| Omega-3 Acid Ethyl Esters | 14 | $1,348 |
| Ranolazine ErRanolazine | 11 | $1,116 |
Paid to pharmacies, not to this prescriber.
Other nuclear cardiology in Philadelphia
- Arthur TopoulosPhiladelphia$36K
- Paco BravoPhiladelphia$1K
- Ross ZimmerPhiladelphia$822
- David SchwartzPhiladelphia$237
- Harvey WaxmanPhiladelphia$20
- Prem SomanPittsburgh$39K
- Leroy MoorePittsburgh$3K
- Rina Gandhi-KulkarniPittsburgh$2K
- John RehderPittsburgh$324
- William FollansbeePittsburgh$58
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.